311 results about "Herpes virus" patented technology

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof in the central nervous system or ex vivo. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a disease (e.g., a neurological disease), preventing a disease (e.g., neurological disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof.

The invention relates to the technical field related to immunological detection, in particular to a mouse anti-porcine herpesvirus type 1 gE monoclonal antibody as well as an immunogen and application of the mouse anti-porcine herpesvirus type 1 gE monoclonal antibody. The amino acid sequences of complementary determining regions CDR1, CDR2 and CDR3 of a heavy chain variable region of the monoclonal antibody or the antigen binding fragment of the monoclonal antibody are respectively as follows: GFSLSTSGMG, IVWGSETGRVTISRDNSK and VRYYDGDDD, and the amino acid sequences of complementary determining regions CDR1, CDR2 and CDR3 of a light chain variable region of the monoclonal antibody or the antigen binding fragment of the monoclonal antibody are respectively as follows: KSSQSLLYSDGKTFLN, LGSNRAS and SSLPHED. The monoclonal antibody can be specifically combined with gE proteins of all subtypes of the porcine herpesvirus type 1, and a porcine herpesvirus type 1 detection kit prepared from the monoclonal antibody has the advantages of high sensitivity, strong specificity, wide detection range, short detection time and the like.

The invention discloses a cat kidney suspension culture cell line suitable for serum-free suspension culture and application of the cat kidney suspension culture cell line. The name of the cell line is F81-B4, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.46350. After 50 generations of continuous subculture, the cells still can maintain the original proliferation level and cellular morphology, the cell number can reach 9.0 * 10 < 6 > / mL after the cells are subcultured at the density of 1.0 * 10 < 6 > / mL for three days, the multiplication time is 22-26 hours, and the cell proliferation speed is equivalent to that in a shake flask when the cells are amplified to a 10L bioreactor for culture. The cell line is highly susceptible to feline parvovirus, feline calicivirus, feline herpes virus, canine parvovirus and canine distemper virus, the virus content of a virus solution harvested 72 h after FPV virus inoculation can reach 107.5 TCID50 / mL, the virus content of a virus solution harvested 24 h after FCV virus inoculation can reach 1010.8 TCID50 / mL, the virus content of a virus solution harvested 48 h after FHV-1 virus inoculation can reach 107.5 TCID50 / mL, compared with an existing F81 adherent cell production process, the production process has the advantages that the production efficiency is high, and the production cost is low. The method has the characteristics of rapid lesion, short virus collection time and high titer. The cell matrix is an ideal cell matrix which can be used for culturing the three viruses.

The present invention relates to an antimicrobial and healing formulation for skin, designed to effectively target and treat skin conditions such as acne caused by Cutibacterium acnes, cold sore lesions due to the herpes simplex virus, and superficial wounds. This unique formulation combines antimicrobial agents, plant extracts and essential oils in specific proportions in order to exert a synergistic action, enhancing their individual efficacy in the treatment of skin conditions and promoting skin healing. The innovative formulation composed of niaouli (Melaleuca viridiflora) essential oil and tea tree (Melaleuca alternifolia) essential oil, chlorhexidine digluconate, Hamamelis virginiana extract, panthenol, glycerol, and propylene glycol. Each ingredient has been selected for its proven pharmacological properties and its synergistic potential. The formulation works in concert to reduce microbial load, alleviate inflammation, and accelerate skin healing, while providing a gentle and effective application.

The application discloses a method for creating a new strain of Carassius auratus gibelii with resistance to Cyprinid herpesvirus 2 (CyHV2) infection, and the method is characterized in that a gene editing technology is used to target knockout gsdf-a a gene and gsdf-b a gene, and an experimental animal infection model of a homozygous knockout strain of the gene obtained by the technology is established. gsdf Results of the experimental animal infection model show that gsdf the CyHV2 infection resistance of the CyHV2 gene knockout Carassius auratus gibelii is significantly enhanced, the histopathological damage of the Carassius auratus gibelii after being infected with the virus is reduced, the expression of a virus protein ORF47 in liver tissue of the Carassius auratus gibelii is reduced, and the transcription level of a virus gene orf46r is significantly reduced. The new strain of Carassius auratus gibelii created by the method can avoid exogenous gene pollution, and has the advantages that the CyHV2 infection resistance of the Carassius auratus gibelii is significantly enhanced.

The invention discloses a monoclonal antibody of feline herpesvirus gB protein, an antigen epitope peptide recognized by the monoclonal antibody and application of the monoclonal antibody. The monoclonal antibody of the feline herpesvirus gB protein comprises an antibody heavy chain and an antibody light chain, wherein a variable region of the antibody light chain comprises a CDR1 consisting of an amino acid sequence as shown in SEQ ID NO.1, a CDR2 of which the amino acid sequence is QVS and a CDR3 consisting of an amino acid sequence as shown in SEQ ID NO.3; a variable region of the antibody heavy chain comprises a CDR1 composed of an amino acid sequence shown in SEQ ID NO.4, a CDR2 composed of an amino acid sequence shown in SEQ ID NO.2 and a CDR3 composed of an amino acid sequence shown in SEQ ID NO.5. According to the research, one specific monoclonal antibody is successfully prepared and obtained, the antigen epitope recognized by the specific monoclonal antibody is identified, and a biological foundation is laid for developing a specific detection reagent of FHV-1.

The invention provides a herpes simplex virus mRNA vaccine as well as a preparation method and application thereof. According to the present invention, through a series of selection and optimization, the antigen protein suitable for preparing the mRNA vaccine, especially the combination of gD2 and gE1, is obtained, and the divalent vaccine prepared based on the antigen protein has excellent effect. The novel mRNA vaccine disclosed by the invention can efficiently induce humoral immune response, cellular immune response and T cell immune response, so that the novel mRNA vaccine can be effectively used for preventing and controlling herpes simplex virus infection, and can simultaneously cover the prevention and control of two viruses, namely HSV-1 and HSV-2.

Herpesviridae glycoprotein B (gB) polypeptides comprising a modified ectodomain is stabilized in the prefusion state, enabling development of inhibitors and vaccines directed against these viral pathogens. Modifications to DI, DII, and DV subdomains are important to stabilization of gB in the prefusion state, and additional modifications result in a further improved stabilization of gB in the prefusion state. The gB can be derived from an Epstein Barr Virus (EBV), a Human Cytomegalovirus (CMV), a Human Herpesvirus 6 (HHV6), a Herpes Simplex Virus 1 (HSV1), or a Varicella Zoster Virus (VZV). Polypeptides, nucleic acid constructs, compositions, and methods of using same to elicit an immune response are described.

The invention provides a recombinant herpes simplex virus and a herpes simplex virus modification method. The herpes simplex virus modification method comprises the step of replacing an ICP4 protein coding gene in a herpes simplex virus genome containing an infected cell protein 4 (ICP4) gene with an hTERTp-fluorescent protein expression cassette. The expression cassette comprises an hTERTp promoter and a fluorescent protein coding sequence controlled by the hTERTp promoter, and the transcription direction is opposite to that of an ICP4 promoter in a genome. The hTERTp-fluorescent protein expression cassette in the recombinant virus obtained by the method disclosed by the invention can be normally expressed in response to telomerase activity. Therefore, the recombinant virus is capable of expressing a fluorescent protein, such as mBaoJin, in a cell having human telomerase activity. Cells infected by the virus can be identified through fluorescence signals, and the higher the telomerase activity is, the stronger the fluorescence intensity is. The virus has wide application value in research of tumor action mechanisms and stem cell action mechanisms, health assessment, screening of tumor drugs, research and development of diagnostic reagents and establishment of animal models.

The invention discloses a self-aggregation-induced emission type photosensitizer and a preparation method and application thereof. The photosensitizer has excellent AIE performance, and singlet oxygen can be efficiently generated after aggregation in a physiological environment; and the photosensitizer can effectively overcome the aggregation-induced quenching phenomenon, and has a synergistic effect with the lovir drugs, so that the anti-herpes virus activity is remarkably improved, and the dosage and side effects are reduced.

Described herein is an oncolytic herpes simplex virus, G47ΔhIL12A, which is G47Δ containing a cassette expressing a transgene, e.g., human IL-12, driven by a spontaneously arising genetically altered HCMV immediate-early (IE) enhancer / promoter. This virus has augmented (A) production of the transgene and increased virus replication while retaining safety. Also provided are methods of use thereof for treating cancer, e.g., glioblastoma (GBM) and triple-negative breast cancer (TNBC).

The present invention relates i.a. to a method for treating or preventing avian influenza virus infections in turkeys comprising administering an effective amount of a rHVT-H5HA COBRA.

The present invention provides compositions for the prevention and treatment of genital herpes, comprising nucleoside modified mRNAs that encode herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, and methods of use thereof.

The present invention relates to a liquid composition characterized in that it comprises: a live attenuated herpes simplex virus 1 (HSV-1); 17.5 mg / mL to 22.5 mg / mL of recombinant human serum albumin (rHSA); less than 5 mg / mL of sucrose; 26 mg / mL to 32 mg / mL of sorbitol; 13.5 mg / mL to 16 mg / mL of potassium phosphate and 3 mg / mL to 7 mg / mL of sodium chloride, wherein the liquid composition comprises no more than 0.01 mM of any of lactose, gelatin, antibiotic and free amino acids.

The application discloses a kind of enveloped virus inactivation preparation based on medium-chain triglyceride and application thereof, the present application relates to the technical field of biological medicine external preparation, including active ingredient and auxiliary material: the active ingredient includes: high-purity medium-chain triglyceride (MCT), preferably octanoic acid (C8) and capric acid (C10) triglyceride mixture, purity ≥99%; The auxiliary material includes: food-grade antioxidant, for preventing oxidation of preparation, the content of food-grade antioxidant is 0.01-0.05%w / w, with medium-chain triglyceride as active ingredient, through the physical and chemical synergistic effect, enveloped virus is efficiently killed, for treating stubborn skin mucosa infection diseases (such as stubborn flat warts, herpes labialis, genital herpes, etc.) caused by human papillomavirus (HPV), herpes simplex virus (HSV-1 / HSV-2), varicella-zoster virus and other enveloped viruses.

The present invention relates to a novel crystalline form of a helicase-primase inhibitor compound, and to pharmaceutical compositions comprising the novel crystalline form, to methods of production of the novel crystalline form, to the crystalline form in medicine and for use in the treatment of herpes viral infections.

The present invention relates to a composition comprising a self-amplifying RNA (saRNA) encoding at least one polypeptide of infectious laryngotracheitis virus (ILTV; Gallid alphaherpesvirus 1, GaHV-1), a polypeptide variant of ILTV, or an immunogenic fragment or epitope thereof, and a pharmaceutically acceptable excipient comprising lipid inorganic nanoparticles (LION).More specifically, the sRNA encodes at least one laryngotracheitis virus polypeptide, an ILTV polypeptide variant, or an immunogenic fragment or epitope thereof, said sRNA comprising a first nucleic acid sequence including nsP1, nsP2, nsP3 and nsP4 which encode non-structural alphavirus proteins, a second nucleic acid sequence encoding at least one ILTV polypeptide, an ILTV polypeptide variant, an immunogenic fragment or an epitope thereof, and also comprising a 5' cap, a 5' UTR upstream of the first nucleic acid sequence, a 26S promoter upstream of the second nucleic acid sequence, a 3' UTR and a poly A tail.

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

The technical problem is to develop a novel armed oncolytic herpes simplex virus (HSV) with G47 delta as a skeleton. Provided is a pharmaceutical composition containing an IL-12 expression-type genetically recombinant herpes simplex virus (HSV) that has a gene encoding a fusion polypeptide in which a 35 kDa light chain (p35) and a 40 kDa heavy chain (p40) of interleukin 12 (IL-12) are linked by two or more elastin motifs, and that has the following characteristics (a) to (c). (a) the ICP6 gene is deleted or inactivated; (b) deletion or inactivation of the gamma34.5 gene; and (c) the alpha 47 gene is deleted or inactivated.

The invention relates to the field of bioengineering, in particular to a recombinant human herpes simplex virus as well as a construction method and application thereof. The recombinant human herpes simplex virus lacks US1, US2, US3, US4 and US5 virulence genes at the same time. The construction method comprises the following steps: constructing a donor plasmid, and constructing a cleavage plasmid; transfecting cells with the cleavage plasmids and the donor plasmids in proportion; and after the transfected cells are incubated, infecting with an HSV-1 virus, purifying, and verifying to obtain the recombinant virus. The donor plasmid constructed by the invention retains non-coding regions among US1, US2, US3, US4 and US5 genes, also retains initiation codons and termination codons of the US1, US2, US3, US4 and US5 genes, is added with a fluorescent tag sequence, and can knock out five virulence genes of HSV-1US1-US2-US3-US4-US5 at the same time. The neutralizing antibody titer result of the recombinant human herpes simplex virus is the same as that of a wild type, and a foundation is laid for vaccine preparation.

A patch composition for targeting herpes virus comprising the following ingredients: a patch base, trisodium phosphate, malic acid, sorbitol, sodium benzoate, cellulose gum, peppermint, sodium saccharin, naringin, wind wheel grass extract, xanthan gum, polyethylene glycol-8, calcium carbonate, hydroxyethyl cellulose, hydroxypropyl guar gum, sodium nitrate, hydrated silica, sodium lauryl sulfate, strontium chloride hexahydrate, tranexamic acid, two-faced needle extract, sodium monofluorophosphate, sea salt, potassium nitrate, sodium chloride, and purified water q.s.

The present disclosure provides a polyribonucleotide encoding a polypeptide comprising a viral antigen from herpes simplex virus-2 (HSV-2); for example, the viral antigens comprise an extracellular domain of HSV-2 glycoprotein B. The polyribonucleotides can be formulated as RNA compositions that can be used to induce an anti-HSV immune response in a subject.

Disclosed is a replication incompetent HSV-1 viral vaccine comprising a modified genome of HSV-1 and at least one antigen. The modification comprises a deletion of internal repeats, an inactivating mutation in ICP47 and an inactivating mutation in the other copy of ICP4. A first antigen of the at least one antigen is driven by a promoter of an immediate early gene, such as ICP4. In a specific example, the HSV-1 viral vaccine expresses antigens from SARS-Cov, SARS-Cov-2 and variants thereof and is used for inducing immune responses against sarbecoviruses in a subject to which the vaccine is administered.

A pharmaceutical composition comprising: i) a herpes gE protein, an active fragment of the protein, a variant of the protein, or a mixture of at least two of them; ii) an immunostimulatory composition comprising a saponin and a CpG oligodeoxynucleotide, or consisting of an adjuvant comprising a saponin and a CpG oligodeoxynucleotide. Use of the pharmaceutical composition in the preparation of a medicament for preventing and / or treating a varicella-zoster virus infection and / or a varicella-zoster virus mediated disease. The pharmaceutical composition achieves an unexpected technical effect and can mediate a stronger immune response.

The invention discloses a medicinal moxa composition for preventing and treating atherosclerosis and suppurative bacterial infection co-disease. The medicinal moxa composition comprises coptis chinensis, radix rehmanniae, polygala tenuifolia, juncus effuses and moxa. The medicinal folium artemisiae argyi composition disclosed by the invention can be used for effectively preventing and treating atherosclerosis and skin suppurative bacterial infection co-diseases through a multi-target synergistic effect. The medicinal moxa composition has the core effects of clearing away heart-fire, inducing diuresis for treating stranguria and promoting blood circulation to remove meridian obstruction, and forms a complete treatment system which uses cold and warm as well as treats both symptoms and root causes by purging fire for removing toxin through coptis chinensis, clearing heat and cooling blood through radix rehmanniae, soothing nerves and promoting intelligence through polygala, inducing diuresis and conducting heat downward movement through juncus effuses and combining moxa floss for warming and dredging meridians, eliminating cold to stop pain, resisting bacteria and diminishing inflammation. By inhibiting inflammatory factors, regulating epithelial cell proliferation and reaction to oxidative stress, regulating fluid shear force, atherosclerosis and Kaposi sarcoma-related herpesvirus infection-related pathways and other mechanisms, the medicinal folium artemisiae argyi composition realizes synergistic prevention and treatment of atherosclerosis and skin infection, and provides a basis for co-disease treatment.

The invention belongs to the field of preparation of high-antibacterial carbon dots, and discloses a high-antibacterial carbon dot, a preparation process and application of the high-antibacterial carbon dot in vaginal gel. The prepared carbon dots are prepared by adopting physical shearing and ultrasonic synergistic pretreatment, then cooperating with microwave gradient energy crushing and stripping, and then performing centrifugation, dialysis purification and vacuum freeze drying, the damage of oxidation or acid treatment to a graphite structure is avoided in the whole process, and the carbon dots have excellent antibacterial and antiviral performance, can effectively inactivate various pathogenic microorganisms, and have good application prospects. Comprise herpes simplex virus, human papilloma virus HPV16, staphylococcus aureus, candida albicans and the like. The invention also optimizes application conditions, is suitable for developing efficient and safe vagina antibacterial gel products, and provides an innovative solution for preventing and treating gynecological infection.

The virus of the present disclosure is a multiple mutant virus in which two or more genes of herpes simplex virus type 2 (HSV-2) are altered and the alteration of the genes is impaired or reduced in gene function.